Down syndrome: Advances in molecular biology and the neurosciences

Journal of Developmental and Behavioral Pediatrics

Volumn 22, Issue 1, 2001, Pages 40-59

  Capone, George T ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KENNEDY KRIEGER INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Brain development; Chromosome 21; Cognitive impairment; Down syndrome; Gene expression; Neurobiology

Indexed keywords

DNA;

ANIMAL MODEL; ARTICLE; BIOMEDICINE; BRAIN FUNCTION; CENTRAL NERVOUS SYSTEM DISEASE; CHROMOSOME 21; COGNITIVE DEFECT; DNA SEQUENCE; DOWN SYNDROME; GENE DOSAGE; GENETIC VARIABILITY; HUMAN; LANGUAGE DISABILITY; MOLECULAR BIOLOGY; MOTOR DYSFUNCTION; NEUROPATHY; NEUROSCIENCE; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL;

EID: 0034762806     PISSN: 0196206X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004703-200102000-00007     Document Type: Article

References (274)

1. Observations on an ethnic classification of idiots
2. A study of somatic chromosomes in nine infants with mongolism
3. Kalmuc idiocy: Report of a case with autopsy with notes on sixty-two cases
4. Early senile dementia in Mongolian idiocy
5. Biomedical Concerns in Persons with Down Syndrome
6. The neurobiologic consequences of Down syndrome
7. Down syndrome children often have brain with maturation delay, retardation of growth, and cortical dysgenesis
8. Six weeks to twenty-one years old: A longitudinal study of children with Down's syndrome and their families
9. Parental origin of the extra chromosome in trisomy 21 as indicated by analysis of DNA polymorphisms
10. Familial Down syndrome due to t(10;21) translocation: Evidence that the Down phenotype is related to trisomy of a specific segment of chromosome 21
11. Down syndrome: Cytogenetical epidemiology
12. Down syndrome: Its frequency in human populations and some factors pertinent to variations in rates
13. The DNA sequence of human chromosome 21
14. Structure of human chromosome 21: For an understanding of genetic diseases including Down's syndrome
15. 10 years of genomics, chromosome 21, and Down syndrome
16. The conceptual bases for the phenotypic mapping of conditions resulting from aneuploidy
17. Down syndrome: Toward a molecular definition of the phenotype
18. A transcript map of the Down syndrome critical region on chromosome 21
19. Molecular neurogenetics: The genome is settling the issue
20. Molecular genetics of Alzheimer's disease
21. Cellular actions of β-amyloid precursor protein and its soluble and fibrillogenic derivatives
22. Expression of the Alzheimer's amyloid precursor gene transcripts in the human brain
23. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
24. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase
25. Altered reactivity of superoxide dismutase in familial amyotropic lateral sclerosis
26. Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons
27. Metabolism of oxygen derivatives in Down's syndrome
28. Immunohistochemistry of superoxide dismutase-1 in developing human brain
29. Attenuation of focal cerebral ischemic injury in transgenic mice overexpressing CuZn superoxide dismutase
30. Relationship of resistance to oxygen free radicals to CuZn-superoxide dismutase activity in transgenic, transfected, and trisomy cell
31. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity
32. Superoxide dismutase, glutathione peroxidase, and lipoperoxidation in Down's syndrome fetal brain
33. The S100 protein family
34. Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a S100β-binding protein
35. S-100β and insulin-like growth factor-II differentially regulate growth of developing serotonin and dopamine neurons in vitro
36. S-100β but not NGF, EGF, insulin or calmodulin is a CNS serotonergic growth factor
37. Appearance of a brain specific antigen (the S-100 protein) during human fetal development
38. Accumulation of S100β mRNA and protein in cerebellum during infancy in Down syndrome and control subjects
39. Neurotransmitters in the regulation of neuronal cytoarchitecture
40. Blockade of NMDA receptors disrupts experience-dependent plasticity of kitten striate cortex
41. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development
42. Glutamate neurotoxicity and diseases of the nervous system
43. The molecular biology of mammalian glutamate receptor channels
44. Cloning of a novel glutamate receptor subunit GluR5: Expression in the nervous system during development
45. Kainic acid seizure syndrome and binding sites in developing rat
46. RNA editing in brain controls a determinant of ion flow in glutamate-gated channels
47. Temporal analysis of the upregulation of GluR5 mRNA editing with age: Regional evaluation
48. Kainate receptor gene expression in the developing rat brain
49. Quantitative localization of AMPA/kainate and kainate glutamate receptor subunit immunoreactivity in neurochemically identified subpopulations of neurons in the prefrontal cortex of the macaque monkey
50. Two new members of the murine Sim gene family are transcriptional repressors and show different expression patterns during mouse embryogenesis
51. The Drosophila single-minded gene encodes a helix-loop-helix protein that acts as a master regulator of CNS midline development
52. Down syndrome-critical region contains a gene homologous to Drosophila sim expressed during rat and human central nervous system development
53. cDNA cloning of a murine homologue of Drosophila single-minded, its mRNA expression in mouse development, and chromosome localization
54. Physical mapping of the holoprosencephaly critical region in 21q22.3, exclusion of SIM2 as a candidate gene for holoprosencephaly, and mapping of SIM2 to a region of chromosome 21 important for Down syndrome
55. Minibrain: A new protein kinase family involved in postembryonic neurogenesis in Drosophila
56. A human homologue of Drosophila minibrain (MNB) is expressed in the neuronal regions affected in Down syndrome and maps to the critical region
57. Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome
58. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1)
59. Shaking down new epilepsy genes
60. The cystatins: Protein inhibitors of cysteine proteinases
61. Mouse cDNAs encoding a trifunctional protein of de novo purine synthesis and a related single-domain glycinamide ribonucleotide synthetase
62. Cystolic biosynthesis of GTP and ATP in normal rat pancreatic islets
63. Hyperuricemia in Down's syndrome
64. Plasma urate levels in mongolism
65. The human GARS-AIRS-GART gene encodes two proteins which are differentially expressed during human brain development and temporally overexpressed in cerebellum of individuals with Down syndrome
66. Isolation, sequence, and developmental profile of a brain-specific polypeptide, PEP-19
67. Molecular genetic characterization and comparative mapping of the human PCP4 gene
68. An immunochemical analysis of the distribution of a brain-specific polypeptide, PEP-19
69. DSCAM: A novel member of the immunoglobulin superfamily maps in a Down syndrome region and is involved in the development of the nervous system
70. Overlapping and differential expression of BIG-2, BIG-1, TAG-1, and F3: Four members of an axon-associated cell adhesion molecule subgroup
71. The consequences of chromosome imbalance
72. Human brain development
73. The brain in mongolian idiocy
74. A statistical note on cerebellar and brain-stem weight in mongolism
75. Brain growth in Down syndrome subjects 15 to 22 weeks of gestational age and birth to 60 months
76. Head circumference of children with Down syndrome (0-36 months)
77. Abnormal neurogenesis and synaptogenesis in Down syndrome brain
78. Decreased cyclin dependent kinase in brain of patients with Down syndrome
79. Decreased transcription factor junD in brains of patients with Down syndrome
80. Neuronal density and synaptogenesis in the postnatal stage of brain maturation in Down syndrome
81. Down's syndrome: Is there a decreased population of neurons?
82. An organizing principle for cerebral function: The unit module and the distributed system
83. Epilepsy in Down syndrome: Clinical aspects and possible mechanisms
84. Spine distribution along the apical dendrites of the pyramidal neurons in Down's syndrome
85. Pyramidal cell abnormalities in the motor cortex of a child with Downs syndrome
86. Dendritic atrophy in children with Down's syndrome
87. Structural abnormalities of the cerebral cortex in human chromosomal aberrations: A golgi study
88. Dendritic and histochemical development and ageing in patients with Down syndrome
89. Synapse elimination and plasticity in developing human cerebral cortex
90. Postnatal delay of myelin formation in brains from Down syndrome infants and children
91. Anomalous brain morphology on magnetic resonance images in Williams syndrome and Downs syndrome
92. Cerebral morphologic distinctions between Williams and Down syndromes
93. Down syndrome: MR quantification of brain structures and comparison with normal control subjects
94. Callosal morphology concurs with neurobehavioral and neuropathological findings in two neurodevelopmental disorders
95. Trisomy 21 (Down's syndrome) glutathione peroxidase, hexose monophosphate shunt and I.Q
96. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro
97. Biomarkers of oxidative stress are significantly elevated in Down syndrome
98. Modification of ion homeostasis by lipid peroxidation: Roles in neuronal degeneration and adaptive plasticity
99. Enhanced production of superoxide anion by microglia from trisomy 16 mice
100. Glutathione levels and nerve cell loss in hippocampal cultures from trisomy 16 mouse: A model of Down syndrome
101. +2 signaling and mitochondrial deficiencies in hippocampal neurons of trisomy 16 mice: A model of Down's syndrome
102. Oxidants as stimulators of signal transduction
103. Antioxidant and redox regulation of gene transcription
104. NK-KB: A crucial transcription factor for glial and neuronal cell function
105. The longitudinal development of infants and young children with Down's syndrome (mongolism)
106. Intellectual and adaptive function in individuals with Down syndrome in relation to age and environmental placement
107. Psychomotor development
108. Interrelationships of biological, environmental and competency variables
109. Infantile spasms in children with Down syndrome
110. Neurological and psychological status of individuals with Down syndrome
111. Mental development in Down syndrome mosaicism
112. Early intervention for infants with Down syndrome: A controlled trial
113. The effect of early intervention and preschool stimulus on the development of Down syndrome children
114. Correlates of intelligence and adaptive behaviour in Down's syndrome
115. Influences on measured intelligence in Down's syndrome
116. The effectiveness of early intervention for children with Down syndrome
117. Effectiveness of early intervention for children with Down syndrome
118. Evaluation of children with Down syndrome who participated in an early intervention program
119. A longitudinal study of children with Down syndrome who experienced early intervention programming
120. Development and plasticity of cortical processing architectures
121. Synaptic activity and the construction of cortical circuits
122. Drugs that increase intelligence? Application for childhood cognitive impairment
123. Individual variability among children with Down syndrome
124. Evidence from two genetic syndromes for a dissociation between verbal and visual-spatial short-term memory
125. Etiologic differences in patterns of psycholinguistic development in children of IQ 30 to 60
126. The development asynchrony of language development in children with Down syndrome
127. Language development in children and adolescents with Down syndrome
128. Speech and language evaluation
129. Auditory and visual sequential memory of Down syndrome and nonretarded children
130. Auditory and visual memory span: Cognitive processing by TMR individuals with Down syndrome or other etiologies
131. Hemispheric asymmetry in Down's syndrome children
132. Lateralisation of speech stimuli in young Down's syndrome children
133. Dichotic verbal processing in Down's syndrome children having qualitatively different speech and language skills
134. Aberrant lateralization of brainstem auditory evoked responses by individuals with Down syndrome
135. Atypical cerebral dominance in Down's syndrome
136. Cerebral specialization for speech perception and movement organization in adults with Down's syndrome
137. Manual and oral praxis in adults with Down's syndrome
138. Development of the superior temporal neocortex is anomalous in trisomy 21
139. Basal Ganglia calcification (BGC) in Down's syndrome (DS): Another manifestation of premature aging
140. Basal ganglia calcification in Down's syndrome
141. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome
142. Presenile dementia in Down's syndrome
143. The development of the pathologic changes of Alzheimer's disease in patients with Down's syndrome
144. Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome
145. Evidence of amyloid β-protein immunoreactive early plaque lesions in Down's syndrome brain
146. The amygdala in Down's syndrome and familial Alzheimer's disease: Four clinicopathologic case reports
147. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: A regional quantitative analysis
148. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease
149. Aberrant expression of bcl-2 gene family in Down's syndrome brains
150. Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome
151. Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue
152. Alzheimer's presenile dementia, senile dementia of Alzheimer's type and Down's syndrome in the middle aged form an age related continuum of pathological changes
153. The substantia nigra and ventral tegmental area in Alzheimer's disease and Down's syndrome
154. Cholinergic therapy for Down's syndrome
155. Magnetic resonance imaging analysis of age-related changes in the brains of individuals with Down syndrome
156. Selective neuroanatomic abnormalities in Down's syndrome and their cognitive correlates: Evidence from MRI morphometry
157. MRI brain changes in subjects with Down syndrome with and without dementia
158. MRI volumes of the hippocampus and amygdala in adults with Down's syndrome with and without dementia
159. Oxidative stress hypothesis in Alzheimer's disease
160. Is Alzheimer's a disease of oxidative stress?
161. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro
162. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease
163. Evidence of an oxidative challenge in the Alzheimer's brain
164. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease
165. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease
166. Electron paramagnetic resonance investigations of free radical induced alteration in neocortical synaptosomal membrane protein infrastructure
167. Brain regional correspondence between Alzheimer's disease pathology and biomarkers of protein oxidation
168. Radical AGEing in Alzheimer's disease
169. Oxidative stress and protein modification in neurodegenerative disease
170. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain
171. β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity
172. Apotosis is induced by β-amyloid in cultured central nervous system neurons
173. A model for β-Amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer's disease
174. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid β-peptide: Role of the lipid peroxidation product 4-Hydroxynonenal
175. Amyloid β-peptide impairs glucose transport in hippocampal and cortical neurons: Involvement of membrane lipid peroxidation
176. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease
177. Brain cytochrome oxidase activity in Alzheimer's disease
178. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses
179. Aging, energy, and oxidative stress in neurodegenerative disease
180. Oxidative stress, glutamate, and neurodegenerative disorders
181. Evidence against the involvement of reactive oxygen species in the pathogenesis of neuronal death in Down's syndrome and Alzheimer's disease
182. Evidence against increased oxidative DNA damage in Down syndrome
183. Defective repair of oxidative damage in mitochondrial DNA in Down's syndrome
184. Expression of DNA excision-repair-cross-complementing proteins p80 and p89 in brain of patients with Down syndrome and Alzheimer's disease
185. The role of intracellular oxidants in apoptosis
186. Amyloid deposition as the central event in the aetiology of Alzheimer's disease
187. The role of the amyloid protein precursor (APP) in Alzheimer's disease: Does the normal function of APP explain the topography of neurodegeneration?
188. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
189. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity
190. Plasma levels of amyloid-β proteins Aβ1-40 and Aβ1-42(43) are elevated in Down's syndrome
191. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome
192. Therapeutic approaches to Alzheimer's disease
193. Enzymes point the way to potential Alzheimer's therapies
194. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology
195. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
196. Association of apolipoprotein E allele 4 with late-onset familial and sporadic Alzheimer's disease
197. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer's disease
198. Apolipoprotein E2 allele promotes longevity and protects patients with Down syndrome from dementia
199. A case-control study of apolipoprotein E genotypes in Alzheimer's disease associated with Down's syndrome
200. The influence of apolipoprotein E isotypes on Alzheimer's disease pathology in 40 cases of Down syndrome
201. ApoE genotypes in Australia: Roles in early and late onset Alzheimer's disease and Down's syndrome
202. Onset of dementia is associated with apolipoprotein E4 in Down syndrome
203. Analysis of the APOE alleles impact in Down's syndrome
204. ApoE genotype and Alzheimer's disease in adults with Down syndrome: Meta-analysis
205. Prevalence of dementia of Alzheimer type and apolipoprotein E phenotypes in aged patients with Down's syndrome
206. A protective effect of apolipoprotein E2 allele on dementia in Down's syndrome
207. APOE genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome
208. Apo E genotypes and risk of dementia in Down syndrome
209. Low density lipoprotein receptor-related protein mediates uptake of cholesterol esters derived from apoprotein E-enriched lipoproteins
210. Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
211. Binding of human apolipoprotein E to synthetic amyloid β peptide: Isoform specific effects and implications for late-onset Alzheimer disease
212. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer's disease
213. Neuropathological changes in Down's syndrome hippocampal formation
214. Red cell superoxide dismutase, glutathione peroxidase and catalase in Down syndrome patients with and without manifestations of Alzheimer disease
215. Preferential localization of copper zinc superoxide dismutase in the vulnerable cortical neurons in Alzheimer's disease
216. Neuronal localization of copper-zinc superoxide dismutase protein and mRNA within the human hippocampus from control and Alzheimer's disease brain
217. Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus
218. Down's syndrome, dementia, and superoxide dismutase
219. Occipito-atlantal translation in Down's syndrome
220. Life-long overexpression of S100β in Down's syndrome: Implications for Alzheimer pathogenesis
221. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease
222. Developmental changes of S-100 protein and glial fibrillary acidic protein in the brain in Down syndrome
223. S100β protein expression in Alzheimer disease: Potential role in the pathogenesis of neuritic plaques
224. Secretory products of macrophages
225. Cytotoxicity of microglia
226. Morphometric analysis of microglia in Alzheimer's disease
227. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease
228. Immune system response in Alzheimer's disease
229. Detection of interleukin-6 and alpha-2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients
230. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease
231. Serum interleukin-6 levels correlate with severity of dementia in Down syndrome and in Alzheimer's disease
232. Neuronal and microglial involvement in β-amyloid protein deposition in Alzheimer's disease
233. The time course of pathological events in Down's syndrome with particular reference to the involvement of microglial cells and deposits of β/A4
234. Microglial cells and amyloid β protein (Aβ) deposition: Association with Aβ40-containing plaques
235. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
236. Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia
237. Psychiatric disorders in persons with Down syndrome
238. Differential rates of psychiatric disorders in adults with Down's syndrome compared with other mentally handicapped adults
239. Brief report: Obsessive-compulsive disorder in adults with Down syndrome
240. Development of a clinic for adults with Down syndrome
241. Association between Alzheimer's disease and Down's syndrome: Clinical observations
242. The natural history of dementia in Down syndrome
243. Seizure disorders in Down syndrome
244. Prevalence and associated features of epilepsy in adults with Down's Syndrome
245. Dementia in Down syndrome: Methods of evaluation
246. A prospective study of Alzheimer's disease in Down's syndrome
247. Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down syndrome
248. Extrapyramidal features in advanced Down's syndrome: Clinical eveluation and family history
249. Genetic basis for a mouse model of Down syndrome
250. Segmental trisomy as a mouse model for Down syndrome
251. Animal models in the study of the biological function of genes on human chromosome 21 and their role in the pathophysiology of Down syndrome
252. Down syndrome and mouse models
253. Neuroanatomical localization and quantification of amyloid precursor protein mRNA by in situ hybridization in the brains of normal, aneuploid and lesioned mice
254. Developmental expression of the gene encoding growth-associated protein 43 (GAP43) in the brains of normal and aneuploid mice
255. Down syndrome and the trisomy mouse: Impact of gene imbalance on brain development and aging
256. Preliminary characterization of the central nervous system in partial trisomy 16 mice
257. Transgenic approaches to cognition
258. A mouse model for Down syndrome exhibits learning and behavioral deficits
259. Impaired short- and long-term memory in Ts65Dn mice, a model for Down syndrome
260. Mapping the human brain: Past, present, and future
261. The human brain project: Neuroinformatics tools for integrating, searching and modeling multidisciplinary neuroscience data
262. Molecular genetics in neurology
263. Dendritic and synaptic pathology in mental retardation
264. Down's syndrome: Prophylaxis and therapy for the frequently comorbid Alzheimer's disease
265. Pharmacologic approaches to cognitive deficits in Alzheimer's disease
266. Update on the development of medication for memory and cognition in Alzheimer's disease
267. Searching for drugs that combat Alzheimer's
268. Clinical trial of indomethacin in Alzheimer's disease
269. Risk of Alzheimer's disease and duration of NSAID use
270. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease
271. Evidence of estrogen benefit in dementia and cognition
272. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease
273. CNS agents and new indications in development